ANI Pharmaceuticals (ANIP) Earnings Analysis
ANI Pharmaceuticals (ANIP) next reports earnings on 2026-08-14, consensus EPS 2.01 USD. Last quarter (2026-05-08) it beat with EPS 2.05 USD vs 1.28 USD est (+60.2%). It has beaten estimates in 7/7 recent quarters (100%). Trailing P/E 18.88.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ANIP next report earnings?
| Next earnings date | 2026-08-14 |
|---|---|
| Consensus EPS estimate | 2.01 USD |
| Revenue estimate | 0.26B |
ANIP earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-08 | 2.05 USD | 1.28 USD | +60.2% | Beat |
| 2026-02-27 | 2.33 USD | 1.99 USD | +17.1% | Beat |
| 2025-11-07 | 2.04 USD | 1.74 USD | +17.2% | Beat |
| 2025-08-08 | 1.8 USD | 1.38 USD | +30.4% | Beat |
| 2025-05-09 | 1.7 USD | 1.37 USD | +24.1% | Beat |
| 2025-02-28 | 1.63 USD | 1.41 USD | +15.6% | Beat |
| 2024-11-08 | 1.34 USD | 1.09 USD | +22.9% | Beat |
Beat rate: 7/7 (100%) over reported quarters with consensus data.
ANIP valuation and analyst view
| Trailing P/E | 18.88 |
|---|---|
| Trailing EPS | 4.287 USD |
| Price / book | 2.89 |
| Dividend yield | 0.00% |
| Market cap | 1.77B |
| Analyst consensus | Buy (7 buy / 3 hold / 0 sell) |
| Avg price target | 91 USD |
Related research pages
Frequently asked questions
When is ANI Pharmaceuticals (ANIP)'s next earnings date?
ANI Pharmaceuticals is next scheduled to report on 2026-08-14, with a consensus EPS estimate of 2.01 USD and revenue estimate of 0.26B.
Did ANIP beat earnings last quarter?
In its 2026-05-08 report, ANIP posted EPS of 2.05 USD versus a 1.28 USD estimate — a beat of 60.2%.
What is ANIP's earnings track record?
Over the last 7 reported quarters with consensus data, ANIP beat estimates 7 times (100%).
What is ANIP's current P/E ratio and EPS?
ANIP trades at a trailing P/E of 18.88 on trailing EPS of 4.287319498900258 USD.
What do analysts rate ANIP?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 91 USD.